Based on the study’s outcomes, the FDA granted accelerated approval to SG for patients with muscular BC who received and demonstrated refractory responses to both platinum-containing chemotherapy and PD-1/PD-L1 inhibitor therapy [46]. This evidence concerns the gene CD274 and breast cancer.